Disease · MONDO_0024331
Trials145
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
1 to 20 of 145
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01183780 | A Study in Second Line Metastatic Colorectal Cancer | Phase 3 | 1,072 | 2015-07-15 | Colorectal Cancer | FLUOROURACIL, IRINOTECAN, LEUCOVORIN, RAMUCIRUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01767857 | A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer | Phase 3 | 643 | 2021-06-29 | Metastatic Colorectal Cancer | BERMEKIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | Phase 1/2 | 557 | 2023-03-13 | Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer | BEMPEGALDESLEUKIN, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02563002 | Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | Phase 3 | 307 | 2022-03-16 | Colorectal Carcinoma | BEVACIZUMAB, CETUXIMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01830621 | BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma | Phase 3 | 282 | 2019-03-11 | Colorectal Carcinoma | NAPABUCASIN | Its record names the disease | ClinicalTrials.gov |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Phase 1/2 | 215 | 2026-02-09 | Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer | EFINEPTAKIN ALFA, PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | Phase 1/2 | 191 | 2025-03-20 | Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer | ENTINOSTAT, PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02337946 | Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma | Phase 2 | 164 | 2019-03-01 | Colorectal Carcinoma | FLUOROURACIL, LEVOLEUCOVORIN CALCIUM, OXALIPLATIN, PANITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02460198 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | Phase 2 | 124 | 2020-08-21 | Colorectal Carcinoma | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00405587 | Safety Study of PLX4032 in Patients With Solid Tumors | Phase 1 | 109 | 2017-08-22 | Malignant Melanoma, Colorectal Carcinoma | VEMURAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT00083720 | Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy | Phase 2 | 87 | 2009-10-23 | Colorectal Neoplasms, Metastases, Neoplasm | CETUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05983367 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | Phase 2 | 76 | 2026-02-20 | Colorectal Cancer, Metastatic Colon Cancer | BEVACIZUMAB, FLUOROURACIL, FOLINIC ACID, IRINOTECAN, OMPENACLID | Its record names the disease | ClinicalTrials.gov |
| NCT00103142 | Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer | Phase 2 | 74 | 2014-04-07 | Colorectal Cancer, Metastatic Cancer | SARGRAMOSTIM | Its record names the disease | ClinicalTrials.gov |
| NCT00891930 | Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab | Phase 2 | 74 | 2016-02-08 | Metastatic Colorectal Cancer | GANITUMAB, IRINOTECAN, PANITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00361842 | Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer | Phase 2 | 65 | 2021-07-02 | Colorectal Neoplasms | FLOXURIDINE, IRINOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT01394939 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | Phase 1/2 | 52 | 2021-01-08 | Colorectal Carcinoma, CRC | IRINOTECAN, PEXASTIMOGENE DEVACIREPVEC | Its record names the disease | ClinicalTrials.gov |
| NCT00786643 | Study of Gamma Interfereon in Metastatic Colorectal Carcinoma | Phase 2 | 48 | 2012-02-22 | Colorectal Cancer | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN | Its record names the disease | ClinicalTrials.gov |
| NCT01047293 | RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | Phase 1/2 | 47 | 2017-03-06 | Colorectal Cancer | BEVACIZUMAB, EVEROLIMUS, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00582660 | Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib | Phase 2 | 40 | 2014-08-07 | Colorectal Adenoma, Colorectal Carcinoma | CELECOXIB | Its record names the disease | ClinicalTrials.gov |
| NCT03531632 | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer | Phase 1/2 | 38 | 2021-11-10 | Colorectal Cancer Metastatic | MGD-007, RETIFANLIMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0024331/trials